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Although there is general consensus that altered brain structure and function underpins 
addictive disorders, clinicians working in addiction treatment rarely incorporate neuroscience-
informed approaches into their practice. We recently launched the Neuroscience Interest 
Group within the International Society of Addiction Medicine (ISAM-NIG) to promote initiatives 
to bridge this gap. This article summarizes the ISAM-NIG key priorities and strategies to 
achieve implementation of addiction neuroscience knowledge and tools for the assessment 
and treatment of substance use disorders. We cover two assessment areas: cognitive 
assessment and neuroimaging, and two interventional areas: cognitive training/remediation 
and neuromodulation, where we identify key challenges and proposed solutions. We reason 
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INTRODUCTION
The past two decades have seen significant advances in 
our understanding of the neuroscience of addiction and 
its implications for practice [reviewed in (1–3)]. However, 
despite such insights, there is a substantial lag in translating 
these findings into everyday practice, with few clinicians 
incorporating neuroscience-informed interventions in their 
routine practice (4). We recently launched the Neuroscience 
Interest Group within the International Society of Addiction 
Medicine (ISAM-NIG) to promote initiatives to bridge this 
gap between knowledge and practice. This article introduces 
the ISAM-NIG key priorities and strategies to achieve 
implementation of addiction neuroscience knowledge and tools 
in the assessment and treatment of substance use disorders 
(SUD). We cover four broad areas: (1) cognitive assessment, 
(2) neuroimaging, (3) cognitive training and remediation, and 
(4) neuromodulation. Cognitive assessment and neuroimaging 
provide multilevel biomarkers (neural circuits, cognitive 
processes, and behaviors) to be targeted with cognitive 
and neuromodulation interventions. Cognitive training/
remediation and neuromodulation provide neuroscience-
informed interventions to ameliorate neural, cognitive, and 
related behavioral alterations and potentially improve clinical 
outcomes in people with SUD. In the following sections, 
we review the current knowledge and challenges in each of 
these areas and provide ISAM-NIG recommendations to 
link knowledge and practice. Our goal is for researchers and 
clinicians to work collaboratively to address these challenges 
and recommendations. Cutting across the four areas, we focus 
on cognitive and neural systems that predict meaningful 
clinical outcomes for people with SUD and opportunities for 
harmonized assessment and intervention protocols.
COGNITIve ASSeSSMeNT
Neuropsychological studies consistently demonstrate that many 
people with SUD exhibit mild to moderately severe cognitive 
deficits in processing speed, selective, and sustained attention, 
episodic memory, executive functions (EF: working memory, 
response inhibition, shifting and higher-order functions such 
as reasoning, problem-solving, and planning), decision-making 
and social cognition (5–10). Furthermore, neurobiologically-
informed theories and expert consensus have identified 
additional cognitive changes not typically assessed by traditional 
neuropsychological measures, namely, negative affectivity and 
reward-related processes (e.g., reward expectancy, valuation and 
learning, and habits-compulsivity) (11–13).
Cognitive deficits in SUD have moderate longevity, and 
although there is abstinence-related recovery (14–16), these 
deficits may significantly complicate treatment efforts during 
the first 3 to 6 months after discontinuation of drug use. Thus, 
one of the most critical implications of cognitive deficits for 
SUD is their potential negative impact on treatment retention 
and adherence, in addition to clinical outcomes such as craving, 
relapse, and quality of life. A systematic review of prospective 
cognitive studies measuring treatment retention and relapse 
across different SUD suggested that measures of processing speed 
and accuracy during attention and reasoning tasks (MicroCog 
test battery) were the only consistent predictors of treatment 
retention, whereas tests of decision-making (Iowa and Cambridge 
Gambling Tasks) were the only consistent predictors of relapse 
(1). A later review that focused on substance-specific cognitive 
predictors of relapse found that long-term episodic memory 
and higher-order EF (including problem-solving, planning, and 
decision-making) predicted alcohol relapse, whereas attention 
and higher-order EF predicted stimulant relapse, while only 
that incorporating cognitive assessment into clinical settings requires the identification of 
constructs that predict meaningful clinical outcomes. Other requirements are the development 
of measures that are easily-administered, reliable, and ecologically-valid. Translation of 
neuroimaging techniques requires the development of diagnostic and prognostic biomarkers 
and testing the cost-effectiveness of these biomarkers in individualized prediction algorithms 
for relapse prevention and treatment selection. Integration of cognitive assessments with 
neuroimaging can provide multilevel targets including neural, cognitive, and behavioral outcomes 
for neuroscience-informed interventions. Application of neuroscience-informed interventions 
including cognitive training/remediation and neuromodulation requires clear pathways to 
design treatments based on multilevel targets, additional evidence from randomized trials and 
subsequent clinical implementation, including evaluation of cost-effectiveness. We propose to 
address these challenges by promoting international collaboration between researchers and 
clinicians, developing harmonized protocols and data management systems, and prioritizing 
multi-site research that focuses on improving clinical outcomes.
Keywords: neuroscience, addiction medicine, treatment, substance use disorder, fMRI, neuromodulation, 
neuropsychological assessment, cognitive rehabilitation
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higher-order EF predicted opioid relapse (8). Working memory 
and response inhibition have also been associated with increased 
risk of relapse among cannabis and stimulant users (8, 17, 18). 
Additionally, variation in response inhibition has been shown to 
predict poorer recovery of quality of life during SUD treatment 
(19). Therefore, consistent evidence suggests that processing 
speed, attention, and reasoning are critical targets for current 
SUD treatments, whereas higher-order EF and decision-making 
are critical for maintaining abstinence. Response inhibition 
deficits seem to be specifically associated with relapse prediction 
in cannabis and stimulant users and also predict quality of life (a 
key non-drug-related clinical outcome) (20).
Practical Considerations: Characteristics 
and Needs of the SUD Treatment 
workforce
The workforce in the SUD specialist treatment sector is diverse, 
encompassing medical specialists, allied health professionals, 
generalist health workers, and peer and volunteer workers (21). 
For instance, in the Australian context, multiple workforce surveys 
over the past decade suggest that around half the workforce have 
attained a tertiary level Bachelor (undergraduate) degree or 
greater (21–24). Similarly, US and European data has shown that 
education qualifications in the SUD workforce are lower than 
in other health services (25). Because the administration and 
interpretation of many cognitive tests are restricted to individuals 
with specialist qualifications, this limits their adoption in the 
sector. In addition, when screening does occur in SUD treatment 
settings, its primary function is to identify individuals requiring 
referral to specialist service providers (i.e., neuropsychology, 
neurology, etc.) for more comprehensive assessment and 
intervention, rather than to inform individual treatment plans.
Two fields in particular have driven progress in cognitive 
assessment practice for generalist workers: dementia, with an 
increasing emphasis on screening in primary care (26, 27), and 
schizophrenia, where cognitive impairment is an established 
predictor of functional outcome (28) necessitating the 
development of a standardized assessment battery specifically 
for this disorder. In the selection of domain-specific tests for the 
Measurement and Treatment Research to Improve Cognition 
in Schizophrenia (MATRICS) standard battery, a particular 
emphasis was placed on test practicality and tolerability, as well 
as psychometric quality. Pragmatic issues of administration 
time, scoring time and complexity, and test difficulty and 
unpleasantness (such as item repetition) for the client should 
be considered (28). These domains and issues are particularly 
relevant for the SUD workforce as well. The dementia screening 
literature has also emphasized these pragmatic issues, leading 
to a greater awareness and access to general cognitive screening 
tools.
Routine Cognitive Assessments in Clinical 
Practice
To date, the majority of the published literature on routine 
cognitive screening in SUD contexts has focused on three tests 
commonly used in dementia screening (29–34): the Mini-Mental 
State Examination (MMSE) (35), Addenbrooke’s Cognitive 
Examination (ACE) (36), and the Montreal Cognitive Assessment 
(MoCA) (37). Due to their development for application in 
dementia contexts, these screening tools placed a heavy emphasis 
on memory, attention, language and visuospatial functioning 
(34). Multiple studies have demonstrated superior sensitivity of 
the MoCA and the ACE scales compared to the MMSE (34, 38). It 
is possible that this arises from the MoCA and ACE including at 
least some items assessing EF (letter fluency and trails) which are 
absent in the MMSE. Indeed, this may demonstrate an important 
limitation of adopting existing screening tools designed for 
dementia in the context of SUD treatment. It can be argued that 
cognitive screening is most beneficial in SUD contexts when 
focused on SUD-relevant domains, rather than the identification 
of general cognitive deficits. Therefore, current neuroscience-
based frameworks emphasise the importance of assessing EF, 
incentive salience, and decision-making in SUD (13, 28, 39, 40). 
As such, there is much to be gained by applying a process similar 
to the MATRICS effort (28, 39, 40) in the SUD field to identify a 
‘gold-standard’ set of practical and sensitive cognitive tests that 
can be routinely used in clinical practice.
Cognitive Assessment Approaches in SUD 
Research
The most commonly used cognitive assessment approach in 
SUD research has been the "flexible test battery". This approach 
combines different types of tests to measure selected cognitive 
domains (e.g., attention, EF). Attention, memory, EF, and 
decision-making are the most commonly assessed domains, 
although there is a considerable discrepancy in the tests selected 
to assess these constructs (41). Even within specific tests, different 
studies have used several different versions; for example, at least 
four different versions of the Stroop test have been employed 
in the SUD literature (1). Another commonly used approach is 
the "fixed test battery", which involves a comprehensive suite of 
tests that have been jointly standardized and provide a general 
profile of cognitive impairment. The Cambridge Automated 
Neuropsychological Test Battery (CANTAB) (42), the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS) 
(43), the Neuropsychological Assessment Battery (NAB) – 
Screening Module (44) and the MicroCog™ (45) are examples of 
fixed test batteries utilized in SUD research (30, 46–48), although 
these too have limited assessment of EF. Another limitation of 
these assessment modules is the lack of construct validity, as they 
were not originally designed to measure SUD-related cognitive 
deficits. As a result, they overemphasize assessment of cognitive 
domains that are relatively irrelevant in the context of SUD and 
neglect other domains that are pivotal (e.g., decision-making). 
A common limitation of flexible and fixed batteries is their 
reliance on face-to-face testing, normally involving a researcher 
or clinician, and their duration, which is typically around 
60-90 min.
To address this gap, a number of semi-automated tests of 
cognitive performance have been developed, including the 
Automated Neuropsychological Assessment Metrics (ANAM, 
developed by the U.S. Department of Defence), Immediate 
Frontiers in Psychiatry | www.frontiersin.org December 2019 | Volume 10 | Article 877
Integrating Neuroscience into Addiction TreatmentVerdejo-Garcia et al.
4
Post-concussion Assessment and Cognitive Testing battery 
(ImPACT), and CogState brief battery, have been used more 
widely, although validation studies to date suggest they may not 
yet have sufficient psychometric evidence to support clinical 
use (49–53). Research specifically in addictions has begun 
to develop and validate cognitive tests that can be delivered 
in client/participants’ homes or via smartphone devices (54) 
(scienceofbehaviorchange.org, 2019). Evaluations of the reliability, 
validity, and feasibility of mobile cognitive assessment in 
individuals with SUD have been scarce, but promising (55–57).
Cognitive assessment via smartphone applications and web-
based computing is a rapidly developing field, following many 
of the procedures and traditions of Ecological Momentary 
Assessment (EMA) (56). The flexibility and rapidity of 
assessment offered by mobile applications makes it particularly 
suited to questions assessing change in cognitive performance 
over various time scales (within hours to over months). For 
example, cognitive performance can be assessed in event-based 
(i.e., participants-initiated assessment entries), time-based 
and randomly prompted procedures that were not previously 
feasible, and or valid, in laboratory testing. While the benefits of 
mobile testing to longitudinal research, particularly large-scale 
clinical trials, appear obvious (57), the rapidity and frequency of 
deployment also provide opportunities to test questions of much 
shorter delays between drug use behavior and cognition. For 
example, recent studies have examined if daily within-individual 
variability in cognitive performance, principally response 
inhibition, was associated with variable likelihood for binge 
alcohol consumption (58). Similarly, influencing the immediate 
dynamic relationship between cognition and drug use has also 
been used for intervention purposes. Web and smartphone 
platforms have been used to administer cognitive-task based 
interventions, such as cognitive bias modification (CBM) training 
(59–61), where cognitive performance is routinely measured as 
a central element of interventions that span several weeks. The 
outcomes of these trials show that mobile cognitive-task based 
interventions are feasible but not efficacious as in a stand-alone 
context (58, 61). However, the combination of cognitive bias 
modification (approach bias re-training) and normative feedback 
significantly reduces weekly alcohol consumption in excessive 
drinkers (59).
Summary of evidence and Future 
Directions
A substantial proportion of people with SUD have cognitive 
deficits. Alcohol, stimulants and opioid users have overlapping 
deficits in EF and decision-making. Alcohol users have additional 
deficits in learning and memory and psychomotor speed. Heavy 
cannabis users have specific deficits in episodic memory and 
attention. Cognitive assessments of speed/attention, EF and 
decision-making are meaningfully associated with addiction 
treatment outcomes such as treatment retention, relapse and 
quality of life (1). In addition, there is growing evidence that 
motivational and affective domains are also implicated in SUD 
pathophysiology and clinical symptoms (8). For example, both 
reward expectancy and valuation and negative affect have been 
proposed to explain SUD chronicity (13). However, to date, there 
have been no studies linking these "novel domains" with clinical 
outcomes. Thus, it is important to explore the predictive validity 
of non-traditional cognitive-motivational and cognitive-affective 
domains in relation to treatment response. While flexible and 
fixed test batteries are the most common assessment approaches, 
data comparability is alarmingly low and future studies should 
aim to apply harmonized methods (41). Remote monitoring 
and mobile cognitive assessment remain in a nascent stage for 
SUD research and clinical care. It is too early to make accurate 
cost-benefit assessments of different mobile methodologies. Yet, 
their potential to provide more cost-effective assessment with 
larger and more representative samples and in greater proximity 
to drug use behavior justifies continued investment into their 
development.
Challenges for Implementation Into 
Practice
One of the main challenges for the cognitive assessment of 
people with SUD is the disparity of tests applied across sites and 
studies, and the lack of a common ontology and harmonized 
assessment approach (13, 62). Furthermore, harmonization 
efforts must accommodate clinicians’ needs, including brevity, 
simplicity, and automated scoring and interpretation (10). 
Mobile cognitive testing is a highly promising approach, 
although its reliability and validity are influenced by a 
number of key factors. Test compliance, or lack thereof, 
seems to be problematic. A recent meta-analysis suggested 
that the compliance rate for EMA (the standard paradigm to 
administer mobile cognitive testing) with SUD samples was 
below the recommended rate of 80% (63). Designs including 
participant-initiated event-based assessments were associated 
with test compliance issues, whereas duration and frequency 
of assessment were not. While the latter finding suggests that 
extensive cognitive assessment may be feasible with mobile 
methods, caution is advised with regard to the scope and depth 
of the data that can be obtained with these brief assessments 
and the validity of data sets collected (64). Remote methods for 
assessing confounds such as task distraction, malingering, and 
"cheating" are not well established or validated. As the capability 
of smartphones, for example, increases, so will the potential to 
minimize or control for such variables. Face-recognition and 
fingerprint technology has been proposed for ensuring identity 
compliance, although this presents ethical issues regarding 
confidential and de-identified data collection from samples that 
engage in illicit drug use (65).
ISAM-NIG Recommendations for 
Cognitive Assessment
As the authors of this ISAM-NIG roadmap, we give the following 
recommendations for future work: 
1. Selecting theoretically and clinically relevant constructs: We 
recommend prioritizing constructs that are theoretically 
implicated in current neurobiological models of SUD 
[reviewed in (66)] and meaningfully related to SUD treatment 
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response and clinical outcomes [e.g., (1, 67, 68)]. These 
include attention/processing speed, response inhibition, and 
higher-order EF/decision-making. Episodic and working 
memory assessments can be particularly indicated in the case 
of alcohol and cannabis users (8).
2. Selecting measures with well-established clinical validity in 
the SUD population: We recommend using measures with 
demonstrated predictive and ecological validity (i.e., their 
scores predict individual variation in meaningful clinical 
outcomes such as treatment response, craving, drug use/
relapse, and quality of life), in addition to reliability. 
Unfortunately, few such measures are currently available. 
The MicroCog test battery and Continuous Performance 
Test (sustained attention/response inhibition) are highly 
reliable and excellent predictors of treatment response (1). 
Delay discounting paradigms and gambling tasks have 
excellent predictive and ecological validity, but the latter 
have been criticized for low reliability and construct validity 
(69). Because the ultimate goal is to incorporate cognitive 
assessment into clinical practice, we recommend conducting 
a Delphi consensus study including both cognitive assessment 
researchers and SUD clinicians to identify a minimum battery 
of measures with adequate psychometric properties AND 
clinical significance.
3. Adopting harmonized cognitive assessment protocols: 
We recommend continuing work towards developing a 
harmonized Cognitive Assessment of Addiction (CAA) 
battery. This battery should be (1) theoretically grounded 
in current addiction neuroscience frameworks; (2) brief 
and easy to administer, to meet the needs and qualifications 
of the SUD workforce; (3) portable and repeatable, 
capitalizing when possible on emerging remote monitoring 
techniques; (4) clinically meaningful in individual-level 
predictive models, i.e., able to identify risk of cognition-
related premature treatment cessation or relapse, cognitive 
phenotypes relevant for predicting response to different 
treatment approaches, or changes in cognitive status relevant 
to treatment progression. The CAA should also address 
challenges specific to international research collaboration, 
including culturally-sensitive contents and appropriate 
translation of instructions.
NeUROIMAGING
The development of functional imaging techniques such as 
Positron Emission Tomography (PET) and functional Magnetic 
Resonance Imaging (fMRI), has allowed the high-resolution 
mapping of the brain in-vivo, in people with SUD. This body of 
work has provided increasing evidence that SUD is associated 
with alterations in the anatomy and the functional brain pathways 
ascribed to reward, learning, and EF. Importantly, emerging 
evidence suggests that neuroimaging versus subjective measures 
in SUD may predict with greater precision addiction-relevant 
cognitive processes (e.g., attentional biases) and treatment 
outcomes (e.g., abstinence) (70–72).
Neuroimaging Methods and Techniques 
Applied to SUD
Functional imaging techniques allowed exploration of whether 
brain dysfunction is implicated in SUD in humans. These 
create images of brain function by relying on proxies, including 
metabolic properties of the brain (e.g., oxygen in PET and 
fMRI, glucose levels in PET) (73). The application of functional 
imaging has been crucial to reveal the impact of SUD on 
human brain function in areas ascribed to cognitive processes 
(e.g., EF, decision-making) and positive and negative emotions 
(see "Cognitive assessment approaches in SUD research" in the 
COGNITIVE ASSESSMENT section).
PET studies have also provided early evidence on the 
neurobiology of SUD (74–77). PET imaging relies on the 
movement of injected radioactive material to identify whether 
the metabolic activity of brain regions is related to cognitive 
functions (73). PET’s invasiveness and high financial costs 
have resulted in a limited number of studies using it, and its 
low temporal and spatial resolutions (i.e., 20–40 min required 
for image generation, with a spatial resolution up to 5 mm3) 
prevented the identification of subtle brain activity alterations in 
SUD samples (73).
The development of fMRI provided a way to overcome these 
limitations. Unlike PET, fMRI is non-invasive, promoting feasibility 
in unpacking the neural correlates of SUD (73). Specifically, 
fMRI generates information about brain activity by exploiting 
the magnetic properties of oxygenated and deoxygenated blood 
(73). Further, fMRI provides information on the brain’s functional 
activity with higher temporal and spatial resolutions than those of 
PET, i.e., within seconds and millimeters, respectively (73). These 
methodological advantages have allowed many studies to map the 
neural pathways implicated in SUD, while providing information 
on brain function within a high spatial and temporal resolution. 
However, a well-described limitation of fMRI analyses is the 
difficulty to control for multiple tests (i.e., statistical thresholds) 
and related false positive errors (78). The neuroimaging 
community has started to implement several strategies to address 
this limitation (79), but the use of liberal thresholds has probably 
inflated false positive rates in earlier studies.
Using multi-modal imaging techniques is warranted to further 
unpack the neural mechanisms of SUD and abstinence. For 
instance, integrating structural MRI (sMRI) data with Magnetic 
Resonance Spectroscopy Imaging, an MRI imaging technique 
that allows investigation of metabolites in the brain, may provide 
insight into the biochemical changes associated with volumetric 
alterations in SUD. Further, conducting brief, repeated task-free 
fMRI studies during treatment/abstinence could provide a better 
understanding of the impact of clinical changes on intrinsic brain 
architecture. An advantage of resting-state functional imaging 
data is the possibility of investigating patterns of brain function 
without restrictive "forces" on brain function placed by a specific 
task. Finally, studying SUD with modalities such as Diffusion 
Tensor Imaging (DTI) may reveal alteration in white matter 
pathways that connect brain regions that are volumetrically 
altered. This approach may inform the pathophysiology of 
volumetric alterations in SUD-relevant brain circuits.
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Brain Systems Implicated in Addiction: 
Insights From Theory
Table 1 overviews key neurobehavioral pathways implicated by 
prominent neuroscientific theories of addiction and a growing 
body of work. These include neurobehavioral systems implicated 
in positive valence, negative valence, interoception, and EF (80–
86). Abstinence may recover and mitigate such brain alterations 
and related cognitive functions, e.g., increase in response 
inhibition capacity, lower stress and drug reactivity, learning new 
responses to drugs and related stimuli. This notion is yet to be 
tested using robust neuroimaging methods that, in conjunction 
with treatment-relevant clinical and cognitive measures, measure 
and track the integrity of specific neural pathways during 
abstinence (see examples in Table 1).
The neurobiology of abstinence has been posited to entail 
two core processes (99). The first is the restored integrity of 
brain function, as drug levels in the central nervous system and 
bloodstream clear out with abstinence. The second is the retraining 
of neural pathways implicated in cognitive changes that enable 
abstinence. These include awareness/monitoring of internal 
TABLe 1 | Overview of addiction-related neurocognitive constructs and related brain circuits, tasks, and interventions.
Positive affect, 
Response (13), 
(80), (82), (84)
Positive affect, 
Anticipation (13), 
(83), (84)
Negative affect 
(13), (80), (82), 
Learning/habit (13), 
(83), (84)
Cognitive control 
(13), (82), (83), (84)
Interoception (83), 
(86)
Brain circuit Medial OFC, ventral 
striatum
Medial OFC, sgACC 
(subgenual)
Amygdala Lateral OFC, 
Dorsal striatum 
(Caudate, putamen), 
Hippocampus
DLPFC, dACC 
(dorsal), IFG
Insula, posterior 
cingulate
fMRI tasks Monetary incentive 
delay (reward 
receipt) (87), 
probabilistic reward 
task (88), activity 
incentive Delay task 
(98)
Monetary Incentive 
delay (reward 
anticipation) (87), 
cue-reactivity (90), 
attentional bias (89)
Cue reactivity (90) 
during withdrawal, 
negative or stress 
cue reactivity
Instrumental reward-
gain and loss-
avoidance task (89)
Stop Signal (91), 
Go-no go (92), 
Stroop (93), 
PASAT-M (97)
heartbeat counting 
task (94), visceral 
interoceptive attention 
task (95)
Cognitive Reward receipt, 
response to reward, 
reward satiation
Motivation, saliency 
valuation, reward 
anticipation, 
drive expectancy, 
approach/attentional 
bias
Acute/sustained 
threat
Stimulus-response 
conditioned habits, 
compulsivity, 
learning reward/loss 
contingencies
Loss of cognitive 
control, disinhibition, 
performance 
monitoring, action/
response selection, 
low distress tolerance
"Momentary mapping 
of the body’s internal 
landscape" (96) during 
craving and withdrawal
Behavior Experience of 
reward with drug 
use, response to 
substance-free 
reward
Increased: attention/
salience of drugs 
and related stimuli, 
reward when 
anticipating drug use.
Experience of 
withdrawal, stress, 
anxiety, anhedonia
Drug use as: 
repetitive, compulsive 
drive, conditioned 
response to seek 
positive affect & 
avoid/mitigate 
negative affect, learnt 
association with 
people, situations, 
places
Drug use even when 
known as harmful 
and in response to 
affective distress
Heightened/lowered 
awareness to drug-
related physical & 
psychological states; 
increase distance 
between cue and 
behavioral response.
Intervention 
strategies
Decrease reward 
value of drug (e.g., 
methadone or nicotine 
patches), suppression 
of mPFC with low 
frequency rTMS 
or cTBS; increase 
reward value of drug-
free activities (e.g., 
behavioral activation, 
physical activity)
Cognitive bias 
modification, 
reappraisal training 
for drug cues, 
exposure therapy, 
motivational 
interviewing, 
contingency 
management
Strategies to address 
negative affect 
(e.g., behavioral 
activation and 
cognitive reappraisal 
training), medication 
that counter stress 
response, rtfMRI 
neurofeedback on 
Insula or sgACC
Strategies 
that weaken 
conditioned drug 
behaviors, memory 
reconsolidation
Strengthen inhibitory/
executive control, 
inhibitory control 
training (e.g., 
Go-No-Go), working 
memory training, 
goal management 
training, stimulating 
DLPFC with anodal 
tDCS or high 
frequency rTMS
Mindfulness-based 
therapies, physical 
exercise
Columns reflect key neurocognitive constructs for addiction research. Identified constructs also map onto the three domains of the Addiction Neuroclinical Assessment 
(ANA) (11) framework: Positive affect (response and anticipation), Negative affect, and Cognitive control map directly onto the three domains of ANA (i.e., Incentive 
salience, Negative affectivity and Executive function). Learning/habit is part of Incentive salience (reward learning); Interoception is at the interface of the three ANA 
domains. Rows reflect functional neuroimaging methods (e.g., fMRI tasks), cognitive/behavioral assessments, and examples of neuroscience informed intervention 
strategies aligned with each of the identified constructs.
ACC, anterior cingulate cortex; cTBS, continuous theta burst stimulation; DLPFC, dorsolateral PFC; IFG, Inferior Frontal Gyrus; mPFC, medial PFC; OFC, orbitofrontal 
cortex; PFC, prefrontal cortex; rtfMRI, real-time functional MRI; rTMS, repeated transcranial magnetic stimulation; tDCS, transcranial direct current stimulation.
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psychological/physiological states (e.g., insula), withdrawal and 
craving (e.g., amygdala); EF (e.g., dorsal prefrontal regions); 
monitoring conflict between short-term goals (e.g., pleasure 
from using drugs, ventral striatum) versus long-term goals 
(e.g., abstinence and improved quality of life; anterior cingulate 
cortex); motivation to use drugs (e.g., orbitofrontal cortex); and 
learning new responses to drug-related and other stimuli (e.g., 
lateral prefrontal and dorsal striatal regions) (99).
Summary of Neuroimaging evidence in 
SUD
Most neuroimaging studies to date have mapped dysfunctional 
neural pathways in SUD. There is a significant lack of work 
that tracks abstinence-related brain changes over time. This 
evidence gap prevents neuroimaging studies from informing 
the identification of treatment targets and clinical practice. It is 
unclear if abstinence (i) leads to recovery of SUD-related brain 
dysfunction (i.e., return to pre-drug onset level, or comparable 
levels to non-drug using controls), (ii) engages additional 
pathways implicated in abstinence-related cognitive, clinical, 
and behavioral changes, and (iii) is predicted by specific brain 
measures assessed pre-treatment. Emerging (but mixed) evidence 
from standard behavioral (e.g., CBT, Motivational Interview, 
Contingency Management) and pharmacological treatments that 
directly affect the central nervous system provides preliminary 
support for these notions, as reviewed in detail in previous work 
[see (100–102)]. This section provides an overview of early 
neuroimaging evidence for brain changes related to abstinence 
and novel interventions (i.e., cognitive training approaches and 
mindfulness-based therapies).
Neuroimaging Evidence in Abstinence
Abstinence may "reverse" brain dysfunction and volume loss 
associated with SUD. Studies have observed increased or 
normalized volumes in global and prefrontal brain regions related 
to abstinence in people with alcohol use disorder (103) and 
cocaine and opiate use disorders (104). PET and DTI studies of 
alcohol and cocaine users showed recovery of brain dysfunction 
and white matter integrity following heterogeneous abstinence 
durations, e.g., from about a month (105, 106), to several months 
(107, 108) and several years (109, 110). Results from fMRI 
tasks of response inhibition in abstinent users also showed that 
reduced brain function typically associated with drug use, was 
"restored" and increased in prefrontal and cerebellar pathways in 
former versus current cigarette smokers (> 12 month abstinent) 
(111, 112), and in former cannabis users (> 28 day abstinent) 
versus non-users (113).
Emerging (but mixed) evidence showed that abstinence 
duration was associated with improved integrity (functional and 
structure) of cortical and prefrontal pathways (109, 111, 114). 
Additionally, abstinence related neuroadaptations have been 
associated with substance use levels [e.g., cocaine dose (115)], 
and performance was improved during cognitive tasks relevant 
to addiction [e.g., processing speed, memory, EF-shifting (104, 
115)]. Thus, abstinence-related brain changes may in part drive 
treatment relevant outcomes.
Neuroimaging Predictors of Abstinence
Several neuroimaging studies have examined whether 
(structural and functional) brain integrity in SUD predicts 
abstinence, with promising results. Studies of brain structure 
in people with nicotine and alcohol use disorders reported 
that increased volume and white matter integrity in prefrontal 
regions, followed by parietal and subcortical areas, most 
consistently segregated abstainers versus relapsers (116–119). 
Studies have examined brain function using fMRI tasks that 
engage cognitive domains relevant to treatment response (cue 
reactivity, attentional bias, error-related activity, reward, and 
emotion processing) (71, 72, 111, 116, 117, 120–124). These 
studies provided evidence that the function of fronto-striatal 
regions in particular, followed by other regions (e.g., cingulate, 
temporal, insular cortices) discriminated responders versus non-
responders, relapsers versus non-relapsers in cigarette smokers 
and people with methamphetamine, cocaine and alcohol use 
disorders (71, 72, 111, 116, 117, 120, 121, 123, 124). Also, the 
activity of fronto-striatal pathways have been shown to predict 
alcohol dosage at 6 month follow-up (122). Studies that used 
other functional imaging techniques such as spectroscopy and 
PET imaging consistently reported that frontal blood flow and 
metabolites (i.e., in prefrontal, insular, and cerebellar areas) and 
the density of dopamine receptors (i.e., in the dorsal striatum) 
predicted treatment outcome in alcohol users (125, 126) and 
relapse in methamphetamine users (127).
Impact of Cognitive Training Strategies
Novel training strategies that target core cognitive dysfunctions 
in SUD have shown promise to restore cognitive alterations and 
help maintain abstinence (128). One example includes cognitive 
bias modification strategies that reduce attentional biases towards 
substance related cues [see study in tobacco smokers (129)]. Such 
strategies may target top-down and bottom-up brain pathways 
(130) implicated in addiction (131). These include increasing the 
activity of top-down EF regions that enhance inhibitory control 
and behavioral monitoring (e.g., dorsal anterior cingulate, lateral 
orbitofrontal cortex), and decreasing reactivity of bottom-up 
pathways implicated in reactivity to drug stimuli, and craving 
(e.g., amygdala).
Early neuroimaging evidence has examined the 
neuroadaptations that occur pre-to-post-cognitive bias 
modification training. These findings are revised and discussed 
in the COGNITIVE TRAINING AND REMEDIATION 
section below. There is a paucity of neuroimaging research on 
other cognitive training and remediation approaches, despite 
promising evidence of neuroplasticity-related changes after 
cognitive remediation in brain injury (132).
Impact of Mindfulness-Based Interventions
Mindfulness-based interventions are being increasingly used for 
the treatment of SUD (133). Although mindfulness does not use 
standard cognitive training/remediation approaches, it has shown 
to improve SUD-relevant cognitive processes such as attention 
and EF (134) as well as substance use outcomes (i.e., reduced 
craving, withdrawal) (135). Mindfulness-based interventions 
Frontiers in Psychiatry | www.frontiersin.org December 2019 | Volume 10 | Article 877
Integrating Neuroscience into Addiction TreatmentVerdejo-Garcia et al.
8
engage two key cognitive processes (i) focused attention, which 
consists of paying attention to a specific stimulus while letting 
go of distractions (e.g., focus on breathing, while experiencing 
craving) and (ii) open monitoring, which refers to the being 
aware of internal and external stimuli (e.g., acknowledging the 
experience of stress, craving, and withdrawal, or environmental 
triggers) with a non-judgmental attitude and acceptance.
The effectiveness of mindfulness-based interventions has been 
ascribed to improved function of prefrontal, parietal, and insula 
regions that are implicated in EF and autonomic regulation (133, 
136), and down-regulation of reactivity in striatal/amygdala 
regions implicated in reward, stress, and habitual substance use 
(136). Only a handful of neuroimaging studies have examined 
brain changes that occur with mindfulness-based interventions in 
SUD. This includes a fMRI study in tobacco smokers that showed 
a 10-session mindfulness-oriented recovery enhancement 
(MORE) versus placebo intervention, decreased activity of the 
ventral striatum, and medial prefrontal regions during a craving 
task and an emotion regulation task (137). Most evidence on 
mindfulness and SUD consists of behavioral studies that showed 
robust effects on cognition, substance use, and craving. Given the 
widespread use of mindfulness-based interventions in clinical 
settings, we advocate the conduct of active placebo-controlled 
neuroimaging studies that map the neurobiology of mindfulness 
in SUD.
Challenges for Implementation Into 
Practice
Overall, there is a paucity of neuroimaging studies of treatment 
and abstinence in SUD. The study methods are very heterogeneous 
which precludes their systematic integration. First, there was 
significant heterogeneity in treatments, with distinct durations 
and hypothesized neurobehavioral and pharmacological 
mechanisms of action, and distinct treatment responses across 
different individuals, SUD and related psychiatric comorbidities. 
Second, control groups varied substantially (e.g., placebo, active 
control treatment, no control group) and brain changes related 
to abstinence were compared to different types of controls 
(e.g., pretreatment baseline in the same group, control group 
of non-substance users, separate SUD group also assessed 
post-treatment). Third, repeated measures study designs had 
varying data testing points (e.g., before, during and at varying 
times post-treatment) that precluded the integration of the study 
findings and mapping treatment-related, trajectories of brain 
changes with abstinence/recovery. More systematic evidence is 
needed to provide sufficient power to measure brain pathways 
relevant to treatment response and to inform clinically-relevant 
treatment endpoints. In order to address this gap, the ISAM-NIG 
Neuroimaging stream recommends the conduct of harmonized, 
multi-site, neuroimaging studies with systematic testing 
protocols of relevance for clinical practice. It is hoped that the 
ISAM-NIG Neuroimaging approach will generate results that 
can be readily integrated and that increase the power to detect 
abstinence-related neuroadaptations.
On one hand, the integration of neuroimaging testing into 
clinical practice can be challenging. MRI scanners are extremely 
expensive to buy, setup, and run safely, and the acquisition 
of high-quality brain images requires extensive specialized 
technical expertise. On the other hand, the availability of MRI 
scans in many hospitals, universities, and medical institutions, 
may provide ideal settings to integrate neuroimaging and 
clinical expertise. MRI scans can be feasible in that they are 
non-invasive, safe, and can be relatively quick (e.g., anatomical 
and resting-state brain scans can take <10 min, and some fMRI 
tasks can last between 10 and 15 min). Outstanding challenges 
to address remain funding sources, the lack of integration in 
the theoretical frameworks between basic research, clinical 
science, and clinical practice. Discipline-specific specialized 
language and practices can also create barriers. We advocate 
using team science to develop a harmonized interdisciplinary 
framework, so that all stakeholders, including clinicians, 
neuropsychologists, social workers and neuroscientists 
interact to inform commonly-agreed testing batteries and most 
profitable directions for future work.
The present review has focused on neuroimaging data mainly 
acquired through fMRI, allowing for visualization of the brain 
networks involved in certain conditions (e.g., abstinence vs. 
relapse). However, it should be noted that the coarse temporal 
resolution of such techniques (1–2 s) impedes determination 
of the temporal activation sequence (in the order of the ms), 
allowing the specific brain activation patterns to be correlated 
with the various cognitive stages involved in the investigated 
processes [e.g., (138)]. Other tools, such as cognitive event-
related potentials (ERPs) in particular, might be more suitable 
for this purpose (139). Nowadays, different studies reveal 
that specific ERP components tagging specific cognitive 
functions (mainly cue reactivity and inhibition) may be used as 
neurophysiological biomarkers for addiction treatment outcome 
prediction (140). Such data may be of great value to clinicians 
for the identification of cognitive processes that should be 
rehabilitated on a patient-by-patient basis through cognitive 
training and/or brain stimulation. However, despite technical 
facilities (cheap tool easily implementable in each clinical care 
unit), several decades of research, and clinical relevance, ERPs 
like other neuroimaging modalities have yet to be implemented 
in the clinical management of SUD.
ISAM NIG Recommendations for 
Neuroimaging
We aim to map how advanced multimodal neuroimaging 
tools—coordinated with relevant clinical and cognitive measures 
agreed upon with a large multidisciplinary team of experts in the 
field—can be used to track the neurobiological mechanisms of 
addiction treatment. As the authors of this ISAM-NIG roadmap, 
we give the following recommendations for future work: 
1. Neuroimaging testing should be harmonized with clinical and 
cognitive tools mapping overlapping systems (see example in 
Table 1).
2. Neuroimaging testing should be feasible and rely on short and 
robust imaging protocols that recruit specific brain pathways 
implicated in relevant clinical and cognitive features of 
addiction (e.g., craving, attentional bias, cognitive control).
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3. Neuroimaging protocols may also incorporate neuroimaging 
measures of brain integrity other than those included in the 
harmonized protocols when focused on discovery science (e.g., 
new fMRI tasks that target novel cognitive constructs, new 
neuroimaging techniques that test distinct properties of 
brain integrity). This would mitigate the risks that complete 
harmonization around existing neuroimaging measures and 
neurobiological models of addiction would stifle new knowledge. 
We cannot exclude that current neuroimaging techniques and 
theories of addiction may not be an accurate/valid representation 
of brain changes that occur with SUD treatment.
4. Imaging testing batteries should be amenable to repeated 
testing so that changes over time can be tracked (i) 
prospectively, to examine if baseline imaging measures predict 
follow up outcomes assessed 1+ times at the end of treatment, 
(ii) longitudinally, to track individual trajectories of brain and 
behavioral change before, during and after treatment, (iii) 
using rigorous double-blind randomized controlled studies 
to map treatment-specific effects in distinct substance and 
behavioral addictions.
5. Multi-site neuroimaging studies using shared protocols will 
be necessary to gain sufficient power to track heterogeneity 
of treatment responses between individuals SUD, to validate 
the protocols and test their reliability. There are excellent 
examples of successful international collaborations that are 
already in place in this area, such as ENIGMA-Addiction 
(141). We aim to leverage these existing collaboration 
initiatives to increase neuroimaging methods reliability and 
validity and studies sample size and representativity, and to 
expand them by incorporating more clinical researchers 
and clinicians.
6. As treatments often consist of individual and combined 
interventions, the distinct and cumulative effects on brain 
changes should be examined. In addition, investigating 
moderating roles of age and sex differences on these 
abstinence-related neuroadaptations is critical. Indeed, 
younger and older people with SUD may show lower and 
greater vulnerability to aberrant neurobiology (142). People 
with different ages and sex may show distinct neuroplastic 
changes with abstinence and these are largely unknown (99, 
143, 144).
7. Brain indices from neuroimaging testing should be examined 
in relation to treatment response variables, whether measured 
as categories (e.g., responders vs. non-responders, relapsers vs. 
non-relapsers) or as discrete measures of addiction (severity 
of addiction symptom scores, number of relapses, duration 
of abstinence, amount of substance used) and related mental 
health, cognitive and quality of life outcomes (e.g., stress, 
mood, socio-occupational functioning).
COGNITIve TRAINING AND ReMeDIATION
Despite recent advances in psychological and pharmacological 
interventions for SUD, relapse remains the norm. A recent meta-
analysis of 21 treatment outcome studies conducted between 
2000–2015 found that fewer than 10% of treatment seekers were 
in remission (i.e., did not meet SUD diagnostic criteria for the 
past 6 months) in any given year following SUD treatment (145). 
The past decade has seen a proliferation of cognitive training 
(CT) intervention trials aimed at remediating or reversing 
substance-related cognitive deficits (146). However, their 
implementation into clinical practice is almost non-existent, 
despite promising results and now having more flexible, precise, 
engaging and convenient modes of delivery (i.e., computer, 
web and mobile application-based approaches). Gathering 
more data in this still-developing area is essential to facilitate 
translation. Even the most widely tested training interventions, 
such as cognitive bias modification, need more data to fully 
appraise their benefit for addiction treatment (147). This section 
summarizes recent advances in CT, identifies limitations in the 
evidence base, and highlights priorities and directions for future 
research to bridge the gap between science and practice. Current 
CT approaches can be broadly divided into: general cognitive 
remediation, working memory training (WMT), inhibitory 
control (or response inhibition) training (ICT), and cognitive 
bias modification (CBM).
Cognitive Remediation
In SUD, general cognitive remediation approaches such as 
cognitive enhancement therapy (CET) and cognitive remediation 
therapy (CRT) aim to reduce substance use (148–150) and craving 
(151) by targeting EF and self-regulation. Cognitive remediation 
has been shown to improve cognition in domains of working 
memory (WM), verbal memory, verbal learning, attention, and 
processing speed (151–154). Positive outcomes have also been 
shown to be associated with increased neuroplasticity in emotion 
regulation-related fronto-limbic networks in individuals with 
schizophrenia and co-morbid SUD (155). A recent study 
delivered 12 two-hour group sessions of clinician-guided CRT 
and computerized CT (Lumosity) (156) over 4 weeks to a sample 
of female residents completing residential rehabilitation and 
found significant improvements in EF, response inhibition, self-
control, and quality of life relative to treatment as usual (TAU) 
(157). Similar research has reported comparable improvements 
in cognitive functioning following CRT (150, 151) and CET 
(148), and improved cognitive functioning has been associated 
with reduced substance use at 3- and 6-month follow-ups (148, 
150). Importantly, CET and CRT also demonstrate preliminary 
efficacy for SUD patients with cognitive impairments (e.g., 
schizophrenia, past head injury) (148, 157). However, their 
duration, intensity, and high cognitive demand—coupled with a 
current paucity of large-scale, methodologically rigorous clinical 
trials—may currently preclude their widespread implementation 
in clinical settings.
Another manualized therapist-assisted group intervention 
is Goal Management Training (GMT), which trains EF and 
sustained attention and emphasizes the transfer of these 
skills to goal-related tasks and projects in everyday life. When 
combined with mindfulness meditation, GMT has been found 
to significantly improve WM, response inhibition and decision-
making in alcohol and stimulant outpatients relative to TAU (158) 
and more recently also in polysubstance users in a therapeutic 
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community (159). A meta-analysis of GMT more broadly 
concluded that it provides small to moderate improvements 
in EF which are consistently maintained at 1–6 month follow-
ups (160). As such, GMT is likely to be an effective candidate 
cognitive remediation approach for SUD treatment; however, 
substantially more research is needed to validate this assertion, 
particularly regarding the translation of cognitive improvements 
into improved substance use outcomes.
working Memory Training (wMT)
The most widely researched EF training intervention, WMT 
(e.g., Cogmed, PSSCogRehab) (161, 162) requires participants 
to repeatedly manipulate and recall sequences of shapes and 
numbers through computerized tasks that become increasingly 
difficult over time (i.e., they are adaptive to the individual’s 
performance). WMT aims to extend WM capacity, so individuals 
can better integrate, manipulate, and prioritize important 
information, with the aim of supporting more adaptive decision-
making that leads to reduced substance use (163). Relative to 
many other approaches, WMT is intensive, typically requiring 
19–25 days of training and as such, retention is often poor (164). 
While WMT has been shown to lead to improvements in near-
transfer effects (i.e., improved performance on similar WM 
tasks), there is limited evidence supporting far-transfer effects of 
WMT on other measures of EF and importantly, on substance-
related outcomes (165). Reduced alcohol consumption 1 month 
after training was reported following WMT in heavy drinkers 
(163), but most studies have failed to demonstrate or even 
measure changes in substance use (165). For example, non-
treatment seekers with alcohol use disorder who were trained 
with Cogmed showed improved verbal memory but no clinically 
significant reductions in alcohol consumption or problem 
severity (166). While a study of treatment-seekers improved WM 
and capacity to plan for the future (i.e., episodic future thinking) 
on a delay discounting task, there was no measurement of 
substance use outcomes (167). Similarly, studies of methadone 
maintenance (168) and cannabis (169) have found no evidence 
of far-transfer effects (e.g., delay discounting), although Rass 
et al. (168) showed WMT-related reductions in street drug use 
among methadone users. Other forms of WMT (e.g., n-back 
training) have reported similar near-transfer but not substance-
use-related findings with methamphetamine patients (170) and 
a mixed group of substance use patients (alcohol, cannabis, 
cocaine) (164). As such, the greatest limitation in the WMT 
literature is the failure to consistently examine substance use 
outcomes and therefore there is insufficient evidence at this 
time to support the utility of WMT as an effective adjunctive 
treatment for SUD.
Inhibitory Control Training (ICT)
Since deficits in inhibitory control are associated with increased 
drug use (171–174), ICT aims to bolster inhibitory control 
through the repeated practice of tasks [e.g., go/no-go (GNG), 
stop-signal task]. Such tasks require individuals to repeatedly 
inhibit prepotent motor responses to salient stimuli (172). In a 
seminal study, a beer-GNG task which trained heavily drinking 
students to inhibit responses to "beer" stimuli resulted in 
significantly reduced weekly alcohol intake relative to students 
trained towards "beer" stimuli (175). A recent RCT of 120 
heavily drinking students found that a single session of either 
ICT or approach bias modification (ApBM, described below) 
led to significant reductions in alcohol consumption relative to 
matched controls (176). Similarly, Kilwein et al. (177) found that 
a single session of ICT (GNG) reduced alcohol consumption and 
alcohol approach tendencies in a small sample (n = 23) of heavily 
drinking men (177). Despite these promising findings, each of 
the aforementioned ICT studies used community samples, and it 
has not yet been established whether these results will generalise 
to treatment seekers.
Two meta-analyses recently concluded that ICT leads 
to small but robust reductions in alcohol consumption 
immediately after training (178, 179). Di Lemma and Field 
(176) reported reduced alcohol consumption in a bogus taste 
test after a single session of ICT or cue-avoidance training 
(approach bias modification). Others have observed reduced 
alcohol consumption 1 and 2 weeks after ICT (163, 177, 180). 
These findings highlight the promise of ICT though there 
remains a paucity of research assessing long-term drinking 
outcomes outside of laboratory settings. Future studies of ICT 
with clinical populations should consider testing multi-session 
approaches akin to WMT. To date, few studies have trialled 
multi-session ICT: One found it to be ineffective (58) for 
heavily drinking individuals, while another found that 2 weeks 
of ICT resulted in modest reductions of alcohol consumption 
among individuals with AUDs, compared to WMT or a control 
condition (181).
Cognitive Bias Modification (CBM)
CBM aims to directly interrupt and modify automatic processes 
in response to appetitive cues. Attentional bias modification 
(AtBM) aims to modify the preferential allocation of attentional 
resources to drug cues by repeatedly shifting attention to neutral 
or positive (non-drug) cues and away from drug-related cues. 
Despite several null findings (182), significant effects have 
included the reduction of alcohol consumption in non-treatment 
seeking heavy or social drinkers (183, 184). Among treatment 
seekers, five sessions of AtBM have been shown to significantly 
delay time to relapse (but not relapse rates) relative to controls who 
received sham training (185). Similarly, six sessions significantly 
reduced alcohol relapse rates at a one-year follow-up relative to 
a sham training condition in a sample of treatment seekers with 
AUD (186). Among methadone maintenance patients, AtBM 
reduced attentional bias to heroin-related words, temptations 
to use, and number of lapses relative to TAU (187). However, 
among individuals with cocaine use disorder, it failed to reduce 
attentional bias, craving, and cocaine use (188). Likewise, 12 
sessions of AtBM vs. sham training during residential treatment 
for methamphetamine use disorder failed to reduce craving and 
preferences for methamphetamine images (189). A systematic 
review of alcohol, nicotine, and opioid AtBM studies concluded 
that despite numerous negative findings in the literature, eight 
out of 10 multiple-session studies resulted in reduced addiction 
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symptoms (particularly for alcohol), but without concomitant 
reductions in attentional bias (190).
Approach bias modification (ApBM), which uses the 
Approach Avoidance Task, requires an avoidance response to 
drug cues (pushing a joystick, shrinking image size) and an 
approach response (pulling a joystick, enlarging image size) to 
non-drug cues. Several trials have examined alcohol ApBM, 
with evidence that short-term abstinence is increased by up to 
30% with four consecutive training sessions during inpatient 
withdrawal (32) and by 8%–13% at 12-month follow-up (186, 
191, 192). Alcohol ApBM has demonstrated relatively consistent, 
moderate reductions in drinking behavior when delivered to 
clinical populations (193), and it was even added to the German 
guidelines for the treatment of AUD (194).
Early neuroimaging evidence has examined the 
neuroadaptations that occur pre-to-post-cognitive bias 
modification training. This work has focused on two samples 
of abstinent alcoholics undergoing an fMRI cue-reactivity 
task (alcohol versus soft drink stimuli) (61, 195). Participants 
showed higher baseline reactivity to alcohol cues within the 
amygdala/nucleus accumbens and the medial prefrontal cortex, 
respectively (61, 195). The same samples, following a 3-week 
implicit avoidance task (versus placebo), showed reduced 
amygdala and medial prefrontal reactivity (61, 195). Notably, 
these brain changes were associated with reduced craving and 
approach bias to alcohol stimuli (61, 195) but not abstinence 
12 months later. While preliminary, these findings suggest that 
neuroadaptations associated with cognitive bias modification 
have clinical relevance and warrant replication in larger SUD 
samples using robust, active placebo-controlled designs.
To date, only one study has been published that trialled ApBM 
in an illicit drug-using sample of non-treatment-seeking adults 
with cannabis use disorder (N = 33). Relative to sham-training, 
four sessions resulted in blunted cannabis cue-induced craving 
(196) but not less cannabis use. Overall, evidence suggests that 
ApBM is associated with reduced approach bias and reduced 
consumption behaviors for alcohol, smoking, and unhealthy 
foods (197). Recently, six sessions of ApBM delivered to 1,405 
alcohol-dependent patients significantly reduced alcohol relapse 
rates at a 1-year follow-up relative to a sham-training condition 
(186). However, as these reductions were also observed following 
AtBM and a combined AtBM and ApBM condition, the authors 
concluded that all active CBM training conditions had a small 
but robust long-term effect on relapse rates.
Finally, a meta-analysis of alcohol and smoking CBM 
studies (both AtBM and ApBM) showed a small but significant 
effect on clinical outcomes for alcohol (but not smoking), but 
a lack of evidence that reduced approach bias led to improved 
outcomes (198). This assertion was challenged by Wiers et al. 
(193) who noted that the review conflated proof-of-principle 
lab-studies and clinical RCTs and different samples (e.g., 
treatment-seeking alcohol dependent individuals vs non-
clinical student populations). Importantly, these populations 
likely have differences in motivation/awareness for receiving 
an intervention to reduce alcohol use, which could explain 
inconsistencies in the reported effectiveness of CBM across 
populations (193).
Summary of evidence and Future 
Directions
Currently CBM, particularly ApBM, appears one of the most 
promising approaches for individuals seeking treatment for 
AUDs; however, its effectiveness for other drugs (aside from 
tobacco) is yet to be established. The most extensively trialled CT 
approach is WMT, which has shown promising results in alcohol 
and stimulants users. However, its high cognitive demand, 
training intensity, and apparent lack of far-transfer effects limit 
its application to clinical populations. ICT holds much promise 
for reducing alcohol consumption in heavy drinkers, but requires 
testing in treatment-seekers. Finally, more intensive group-
based approaches such as CRT/CET and GMT may improve 
EF and quality of life; however, their impact on substance use 
outcomes remains largely untested. Synergistic approaches now 
warrant exploration. Indeed, a study that combined WMT and 
AtBM (199) has shown promising feasibility and improved EF, 
though substance use outcomes were not assessed. It may also 
prove fruitful to adopt staggered CT approaches, capitalizing 
on the brain,s capacity to repair itself (neuroplasticity) during 
withdrawal, early and later abstinence by strengthening cognitive 
control (e.g., using ICT) and dampening cue-reactivity (e.g., 
using CBM), prior to engaging in more intensive and cognitively 
demanding but ecologically valid group training for more 
extensive remediation (e.g., using GMT).
Challenges for Implementation Into 
Practice
While there may be logistical challenges to the adoption of CT 
in clinical practice (e.g., cost, lack of time, training requirements, 
etc.), the main impediment to implementing CT in clinical 
practice is the absence of robust evidence for treatment success 
of any one particular approach. This is largely due to the vast 
heterogeneity of studies, particularly regarding differences in 
treatment settings, samples (clinical vs. non-clinical populations), 
cognitive intervention approaches, number and duration of 
training sessions, targeted mechanisms, targeted drugs of 
concern and varying primary outcome measures. Similarly, 
the absence of brief, ecologically valid, easily-administered 
measures of cognition precludes the identification of candidates 
who are most likely to benefit from CT (e.g., individuals with 
the poorest WM or the strongest attentional bias). As such, 
the evidence base for CT remains hampered by (1) the marked 
lack of studies on clinical populations, (2) the counter-intuitive 
neglect of assessing relevant substance use outcomes, (3) the 
lack of adequately-powered RCTs, (4) the limitations of research 
designs, (5) lack of attention to individual-level trajectories 
of cognitive improvements in relation to substance use and 
quality of life outcomes (precision medicine approach), and 
(6) a simple focus on direct relations between cognitive deficits 
and outcomes without considering person and environmental 
mediators and moderators of this relation (14). Despite positive 
signals from proof-of-concept studies and pilot RCTs, they 
require replication and testing with suitable control conditions in 
order to demonstrate their applicability in clinical settings. These 
limitations highlight the need for a harmonization approach that 
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promotes greater standardization in cognitive training protocols 
and assessment of its effectiveness (i.e., routine assessment of 
substance use outcomes). Since the software and manuals of 
some of the most promising interventions (e.g., CBM, GMT) are 
well-developed and reproducible, we should advance towards 
optimized shared protocols that can promote international 
collaborations and multi-site studies. These recommendations 
will elucidate what works, for whom and under what conditions 
(i.e., identifying neurocognitive phenotypes). This knowledge 
will then guide the adoption of CT to improve outcomes for 
people seeking treatment for SUD.
ISAM-NIG Recommendations for 
Cognitive Training and Remediation
As the authors of this ISAM-NIG roadmap, we give the following 
recommendations for future work: 
1. The a priori publishing of research protocols: To improve the 
consistency of cognitive training trials we encourage the 
publishing of research methodologies and protocols. This will 
permit replication studies to aid the consolidation of a disparate 
evidence base and help determine the optimal training duration 
and frequency to be implemented in real world clinical settings.
2. Adopting consistent training paradigms and tailored, context-
relevant stimuli: A challenge for CBM research is the absence of 
consensus on optimal sham training conditions (e.g., matched 
stimuli with different push-pull contingencies) and optimal 
approach stimuli (e.g., whether to use neutral stimuli or 
healthier alternatives such as non-alcoholic beverages) (200). 
In the context of both CBM and ICT, utilizing personalized/
tailored stimuli may increase engagement and effectiveness. 
For avoidance or "no-go" stimuli this might involve only 
using beverage types/brands that are regularly consumed by 
an individual, or images of illicit drug use and paraphernalia 
reflecting their preferred route of administration. Similarly, 
approach or "go" stimuli could encompass positive 
motivational images representing an individual’s personal 
goals, values, and aspirations (family, employment, hobbies, 
etc.), which are drawn on heavily in most psychosocial 
interventions. Furthermore, co-design with consumers and 
end-users is a fundamental step to developing interventions 
that will be implemented successfully in practice.
3. Ensuring targeted constructs are measured in cognitive training 
trials: Future research protocols must adopt pre- and post-
intervention measures that will elucidate changes in targeted 
mechanisms, thereby integrating neuroscience into addiction 
treatment. Importantly, these protocols should enable 
moderation and mediation analyses using psychophysiological 
measures (e.g., EEG, skin-conductance) in order to address issues 
regarding the notorious lack of reliability of traditional measures 
(e.g., the implicit association task and the approach avoidance 
task) (192, 201, 202) and thereby more accurately identify 
individuals most likely to benefit from adjunctive approaches.
4. Adopting and standardizing SUD-related outcome measurement: 
Future research needs to test cognitive interventions in real-
world clinical settings and assess meaningful SUD clinical 
outcomes (i.e., reduced substance use, reduced cue-craving). 
Clear evidence of reduced harm and consumption is likely to 
appeal to both clinicians and individuals under their care, thus 
driving this improved addiction treatment effort.
NeUROMODULATION
The exponential growth in our understanding of the neural 
circuits involved in drug addiction over the last 20 years (3, 203–
205) has been accompanied by the introduction of non-invasive 
brain stimulation technologies (NIBS) capable of modulating 
brain circuits externally (outside of the skull), such as transcranial 
magnetic stimulation (TMS) and transcranial electrical 
stimulation (tES). Technical advances in NIBS has increased 
hopes to find clinical applications for NIBS in addiction medicine 
(206). New FDA approval of NIBS technologies in depressive and 
obsessive-compulsive disorders, which have overlapping brain 
circuits with SUD, has raised these expectations to a higher level. 
There are other emerging areas of NIBS for addiction medicine, 
such as focused ultrasound stimulation (FUS) and transcranial 
nerve stimulation (tNS). Furthermore, other technologies exist 
that target neural circuits noninvasively that can be classified 
as "neuromodulation", such as fMRI- or EEG-neurofeedback 
(NF), whereby individuals can change their own brain activity 
in real time using a brain-computer interface. However, this 
section will primarily focus on tES/TMS/NF. We will review 
potential targets, ideal scenarios, and complexities in the field 
of neuromodulation for addiction treatment and then conclude 
with a few recommendations for future research.
Potential Targets for Neuromodulation
Targets in the field of neuromodulation should be defined across 
multiple levels, from behavior, cognitive process, and neural circuit. 
The NIMH research domain criteria (RDoC) have provided a 
research framework for mental health disorders that include these 
levels of targets for neuroscience-informed interventions including 
neuromodulation. While this framework was not specifically 
designed for addiction science, it is still a helpful resource. In 
RDoC terminologies, three main domains are more frequently 
considered for addiction medicine: positive valence, negative valence, 
and cognitive systems with a predominant focus on EF (13, 207). 
Within the positive valence domain, non-drug and drug-related 
reward processing (drug craving) are the most favorable multi-level 
targets for addiction treatment. Within the negative valence domain, 
acute or chronic withdrawal/negative reinforcement, anhedonia, 
and negative mood/anxiety comorbidities should be considered. 
EF with a broad definition has also potential to be targeted in 
neuromodulation (208). For more details, please see Table 1.
Brain Stimulation Studies in SUD
There is a trend of reporting positive results in tDCS and rTMS 
trials in SUD that is being reflected in systematic reviews and 
meta-analysis. In a meta-analysis published in 2013 on 17 eligible 
trials, Jansen, et al., reported that rTMS and tDCS on DLPFC 
could decrease drug craving (209). A meta-analysis of 10 rTMS 
studies identified a beneficial effect of high-frequency rTMS on 
December 2019 | Volume 10 | Article 877Frontiers in Psychiatry | www.frontiersin.org
Integrating Neuroscience into Addiction TreatmentVerdejo-Garcia et al.
13
craving associated with nicotine use disorder but not alcohol (210). 
Another meta-analysis published in 2018 by Song, et al., including 
48 tDCS and rTMS studies targeting the DLPFC, reported positive 
overall effects on reducing drug craving and consumption with 
larger effect for multi-session interventions compared to single-
session interventions (211). A recent meta-analysis with 15 studies 
using tDCS among nicotine dependents reported positive effect on 
craving and consumption (212). However, there is a large variation 
in methodological details (mainly ignored in meta-analyses) that 
makes it hard to find trials replicating previous findings using same 
stimulation protocols. Some of these methodological variations 
are being introduced below with few examples.
Figure 1 depicts the distribution of published tES/TMS 
studies based on their target areas. Most but not all published 
tES/TMS studies (90%) have targeted the DLPFC in order 
to indirectly target other areas within the EF network or 
other limbic/paralimbic areas through their connections 
to the DLPFC. As an example, Terraneo et al. showed that 
applying 15-Hz stimulation to the left DLPFC can reduce self-
reported craving [visual analogue scale (VAS)] and cocaine 
use (urinalysis) among patients with cocaine use disorder 
randomized to receive active or sham repetitive TMS (rTMS) 
(213). In another study, Yang et al. showed that electrical 
stimulation over the DLPFC helps lower cigarette craving in 
nicotine-dependent individuals (214). Participant smokers 
underwent 1 session of real and sham transcranial direct current 
stimulation (tDCS) in a cross-over setting with 30 min duration 
and 1-mA intensity. There are studies targeting other areas than 
the DLPFC within the frontal cortex, such as inferior frontal 
gyrus, ventromedial prefrontal, or middle frontal cortices. As 
an example, Kearney-Ramos et al. demonstrated that applying 
continuous theta burst stimulation (cTBS) as a type of TMS 
to the ventromedial prefrontal cortex could attenuate the cue-
related functional connectivity (215). In another study, Ceccanti 
et al. found out that deep TMS (dTMS) on the medial prefrontal 
cortex (MPFC) decreased craving and alcohol intake in people 
with alcohol use disorder. There are also studies targeting 
motor cortex and temporoparietal areas which have shown that 
tDCS reduces behavior in tobacco users. To conclude (as shown 
in Figure 1), the distribution of international resources across 
all these circuit/process/behavior targets provides interesting 
explorative results to date. Ignoring these methodological 
variations could result in positive results in meta-analysis 
reports. However, considering these methodological details 
would make it hard to introduce a stimulation protocol with 
enough evidence for clinical use. There is a critical need in the 
international NIBS research community to focus on one or two 
main targets to explore any potentially replicable effects that 
could determine suitable avenues for clinical application.
Application of other areas of NIBS such as FUS, tNS in 
addiction medicine is limited to a few case reports. Beyond 
NIBS, invasive brain stimulation technologies like deep brain 
stimulation (DBS) are only just emerging as approaches in 
addiction medicine with only a few case reports or pilot trials 
in the literature. Consequently, the lack of robust evidence for 
invasive neuromodulation precludes any judgment regarding its 
clinical utility.
Challenges for Implementation Into Practice
There are 96 original tES/TMS publications in addiction 
medicine as of May 1, 2019 mainly reporting positive results with 
one to over 20 sessions of stimulation (Figure 2). Large space of 
methodological parameters to select from, small sample sizes, and 
lack of replication across different labs make it difficult to draw 
firm conclusions regarding its effectiveness. Published tES/TMS 
evidence for addiction treatment has been generated by labs in 14 
countries so far (Figure 3). To focus these efforts, there is a need 
for an international roadmap to harmonize the current activities 
in the field across the world using methodologically rigorous 
designs. We hope ISAM-NIG along with other international 
collaborative networks like International Network of tES/TMS 
FIGURe 1 | Brain areas targeted with inhibitory (i) and excitatory (e) protocols in 96 tES/TMS studies among people with substance use disorder (as of May 1, 2019) 
(ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; FP, frontal pole; IFG, inferior frontal gyrus; PCC, posterior cingulate cortex; SFG, superior 
frontal gyrus; SMFC, superior medial frontal cortex; tES, transcranial electrical stimulation; TMS, transcranial magnetic stimulation; TP, temporoparietal).
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Trials for Addiction Medicine (INTAM) can serve to develop 
and navigate this roadmap. The ISAM-NIG neuromodulation 
roadmap should also align with ISAM-NIG roadmaps in other 
areas like brain imaging, cognitive assessments or cognitive 
training, and this publication is the first attempt at this initiative. 
These domains of clinical addiction neuroscience can then 
work hand-in-hand to create tangible outcomes in daily clinical 
practice. The challenges for implementing neuromodulation 
studies into practice are summarized below:
1. How to move beyond single session interventions: 44% of the 
tES/TMS studies have recruited a single session of intervention 
to investigate potential effects to then move forward to 
multiple session studies (Figure 2). By comparison, most of 
the medications, we use in daily clinical practice in psychiatry 
today probably do not show significant effects with a single 
dose. Even adding a sensitive biomarker like a human brain 
mapping measure using fMRI will not be sufficient for a “no-
go” or “fast-fail” decision. In a recent trial with NIMH fast-
fail framework, 8 weeks of medication was being considered 
as the minimum dosage of intervention (216). Meanwhile, 
running multi-session trials is costly and decisions between 
the wide range of available parameters to apply and measure 
are complex.
2. How to narrow down key brain targets and relevant SUD-
relevant cognitive processes/behaviors: There is a wide range 
of potential targets for neuromodulation. There is not a 
consensus on a framework that specifically defines (i) key 
neuromodulation targets, (ii) their relevant substance use, 
cognitive, and clinical outcomes, as different brain pathways 
are ascribed to heterogeneous neurobehavioral processes 
(Table 1), (iii) measurement instruments of desired outcomes 
with highest psychometric properties.
3. How to find the best target population/timing for intervention/
contextual treatment: Timing of neuromodulation 
intervention [before treatment, before initiating abstinence, 
during early abstinence (detoxification), after early 
abstinence (maintenance)] and contextual treatment 
(pharmacotherapies, psychosocial interventions, cue 
exposure, cognitive remediation, etc.) in parallel to 
neuromodulation are important areas for future explorations 
with specific considerations in different SUDs.
4. How to optimize the large parameter space within each NIBS 
technology at the individual level: There is a new effort to 
optimize the stimulation parameter for each individual subject 
based on their subjective responses or objective biomarkers in 
closed-loop stimulation. Bayesian optimization protocols have 
introduced an interesting area with initial positive response 
FIGURe 3 | International contribution to the published evidence with tES/
TMS in people with substance use disorder. Contribution of 14 different 
countries (as of May 1, 2019) in the filed confirms the importance of 
international partnership to improve quality of research in the field. tES, 
transcranial electrical stimulation; TMS, transcranial magnetic stimulation.
FIGURe 2 | Number of sessions in 96 TMS/tES studies among people with 
substance use disorder. Around half of the published studies in the field 
have used just a single session of intervention (as of May 1, 2019). tES, 
transcranial electrical stimulation; TMS, transcranial magnetic stimulation.
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with transcranial alternating current (tACS) stimulation (217). 
Additionally, personalized brain treatment targets can be 
identified using neurofeedback machine learning approaches 
that discriminate distinct patterns of brain function within 
each individual, instead of a priori brain regions (or their 
connectivity) across various individuals (218).
Neurofeedback Studies in SUD
Real-time neurofeedback allows online voluntary regulation 
of brain activity and has shown promise to enhance ascribed 
cognitive processes in health and psychopathology (219–
221). Participants can monitor their brain function in real 
time through a brain computer interface (BCI), typically 
showing a thermometer representing the "temperature" of 
which increases/decreases in real time, to reflect changes in 
the level of brain function. Neurofeedback aids participants 
to voluntarily change brain function online using distinct 
cognitive strategies (e.g., focus on and away from drug-related 
stimuli). Neurofeedback has been most consistently tested in 
ADHD and other psychopathologies, with very early evidence 
being available in SUD.
Neurofeedback is a promising tool that enables mapping 
of the causal mechanisms of SUD. As core brain dysfunction 
is identified within a SUD, neurofeedback can be used as a 
personalized intervention to enhance and recover underlying 
dysfunctional neurocognitive pathways. Neurofeedback can 
source and target brain activity using distinct brain imaging 
techniques including EEG and fMRI (222).
EEG-based neurofeedback allows individuals to modulate the 
intensity of brain oscillations at specific frequencies (e.g., alpha, 
beta, theta, alpha-theta, theta-alpha). These protocols have often 
been used in conjunction with sensorimotor rhythm training (223) 
to improve efficacy in SUD. EEG-based neurofeedback studies 
have targeted brain function in varying SUD groups including 
alcohol, opioid, and stimulant use disorders [see detailed review 
here (224)]. This body of work led to mixed evidence of effects 
(and lack of) on abstinence in the week and months following 
neurofeedback training, as well as reduced disinhibition, craving, 
and severity of dependence symptoms. A paucity of studies has 
shown that these effects were stronger when EEG neurofeedback 
was used in conjunction with existing standard psychological, 
pharmacological, and rehabilitation treatments.
Real-time fMRI (rtfMRI)-based neurofeedback has the 
potential to provide insight in understanding the mechanisms of 
SUD underpinned by deep brain nuclei [e.g., striatum, amygdala 
(80)] the activity of which is unlikely to be robustly measured via 
surface EEG. Feedback can be provided on the level of activity 
of single or multiple a priori regions of interest, the strength of 
the connectivity between multiple regions, and patterns of brain 
activity identified with machine learning methods (e.g., support 
vector machine) (218). A handful of studies have used rtfMRI 
neurofeedback in SUD [for a review, see (12)]. This body of work 
focused largely on nicotine (225–230) and alcohol use disorders 
(231, 232).
Most of these studies focused on a priori brain regions of interest, 
most commonly the anterior cingulate cortex, medial prefrontal 
cortex, and other regions—as well as brain connectivity—were 
used as source for feedback from single studies (OFC, dorsomedial 
and dorsolateral prefrontal regions, insula and ventral striatum). 
Several neurofeedback studies required participants to modulate 
brain function during craving tasks (e.g., largely cue reactivity 
tasks that entail watching drug-related pictures). This body of 
work shows that patients could modulate brain function in the 
target regions, and provides mixed evidence on the presence and 
absence (226, 227, 229) of associations between changes in brain 
activity/connectivity and the severity of drug craving.
In EEG and rtfMRI neurofeedback studies, the significant 
lack of active placebo controlled and well-powered studies (e.g., 
comparison with a group with sham feedback) warrants the 
conduct of more systematic work to determine the efficacy of 
rEEG and rtfMRI-based neurofeedback.
ISAM NIG Recommendations for 
Neuromodulation
As discussed above, there is a growing hope that neuromodulation 
can play a role in the daily practice of addiction medicine. 
However, the lack of rigorous designs does not provide strong 
enough evidence to give a green light for clinical use. With frequent 
negative trials for new pharmacological interventions in addiction 
medicine, governmental agencies across the world are seriously 
looking for new hopes for any intervention that can bring positive 
results in well-powered double-blinded sham/active controlled 
randomized trials. As the authors of this ISAM-NIG roadmap, we 
give the following recommendations for future work: 
1. Creating international platforms that facilitate consensus 
on key targets for neuromodulation and outcome measures 
of efficacy: Addiction neuroscience suffers from the lack 
of international collaborations based on shared matrix of 
multilayer targets and outcome measures. We hope that 
ISAM NIG can bring together a critical mass of expert 
multidisciplinary scientists across the world to contribute in 
development of this international consensus.
2. Setting an agreed-upon minimum international standards 
to produce high quality evidence on the efficacy of 
neuromodulation in SUD: An overview on the scientific rigor 
in the published trials on tES/TMS for addiction medicine 
shows many methodological gaps (233). New potential 
solutions to address this may include shared protocols across 
labs internationally with leadership of expert scientists in the 
field, the development of quality control checklists and Delphi 
initiatives to reach a consensus on minimum standards.
3. Increase the power of neuromodulation experiments: Over 
80% of tES/TMS/NFB studies reported 30 or less subjects in 
each of their arms. Sample sizes can be boosted using multi-
site studies with shared protocols with or without shared 
funding and replication of previous and ongoing studies 
and trials across distinct laboratories. Larger samples will be 
instrumental to (i) increase the power to detect existing effects 
(or lack of), (ii) increase external validity (while accounting for 
inter-individual variability), (iii) make predictive modeling 
for responders and non-responders possible.
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4. We also need to have studies with multi-session interventions 
and long term follow-up to examine the efficacy in tES/
TMS/NF over time, particularly if it increases prolonged 
abstinence.
5. Strategize research efforts to focus available resources to 
examine the clinical feasibility/efficacy of neuromodulation: 
Huge parameter space in almost all areas of neuromodulation 
prevent providing high quality evidence necessary to inform 
clinical practice. Pharmaceutical companies are one of the 
main drivers of drug developments. There is no big company 
in the field of non-invasive neuromodulation and few new 
ones for TMS are still considered as "small businesses" (less 
than 250 employees). Efforts that pool sources of research 
support, e.g., targeted governmental funds and/or "crowd 
sourcing"-type collective international efforts may support 
the development and testing of harmonized neuromodulation 
protocols/target sites for intervention, in order to provide 
high quality, well-powered evidence.
CONCLUSIONS
We reason that incorporating cognitive assessment into 
clinical practice in addiction treatment requires identification 
of constructs that predict meaningful clinical outcomes, 
streamlining of measures for clinical usability while improving 
retest reliability and ecological validity, and application of 
technology for remote monitoring and scalability. Translation 
of neuroimaging measures to clinically meaningful treatment 
outcomes requires developing imaging biomarkers that have 
mechanistic, diagnostic, and prognostic value. It also requires 
testing the cost-effectiveness of introducing brief, targeted brain 
scans, and deriving quantitative predictors of successful treatment 
outcome. Application of cognitive training/remediation and 
neuromodulation requires additional evidence from randomized 
trials and clear pathways to implementation. These translation 
efforts need to address all substance-related disorders. To 
date, most neuroscience studies have focused on alcohol, 
nicotine, cannabis, and stimulants, whereas opioids have been 
underrepresented. The promise of translational neuroscience will 
only be fulfilled if we can provide novel and effective solutions 
to pervasive addiction problems, for example, the current opioid 
crisis. Translation efforts should also factor in the heterogeneity 
of SUD populations in terms of principal drug of choice, patterns 
of polysubstance use and psychiatric comorbidities. In this 
regard, assessment and intervention protocols need to advance 
towards personalized approaches, by capitalizing on advanced 
machine learning applications.
Cognitive assessments and neuroimaging methods can 
elucidate mechanistic multi-level targets (biomarkers) with 
neural/cognitive/behavioral levels for neuroscience-informed 
individualized interventions (Figure 4). Neuromodulation and 
cognitive training interventions along with neuropharmacological 
agents could form multilevel adjunctive interventions based 
on these targets. The effects of these multilevel interventions in 
successfully targeting these mechanisms (biomarkers) should be 
assessed using cognitive and neural mapping measures. There 
remain many challenges to implementing neuroscience-informed 
FIGURe 4 | Neuroscience-informed addiction medicine in closed-loops. Cognitive assessments and different neural mapping technologies will introduce 
mechanistic targets (biomarkers) with neural/cognitive/behavioral levels for a combination of neuromodulation and cognitive interventions. Effects of interventions 
in successfully modifying these targets (biomarkers) are assessed with cognitive and neural mapping measures. Predictive models for treatment efficacy are 
optimized with Bayesian algorithms based on the pragmatic multilevel assessments. Interventions can be optimized in closed-loops to engage targets and consider 
personalized variations toward precision addiction medicine. Psychopharmacological interventions are not included in this roadmap paper; however, they could be 
delivered alongside and potentially augment cognitive training and neuromodulation.
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addiction treatments. We propose to address these challenges 
by promoting international collaboration between researchers, 
clinicians, and industry, developing harmonized protocols and 
data collection/sharing platforms, and prioritizing research that 
focuses on improving clinical outcomes in SUD.
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